DRD2 and Alzheimer disease: Also, GSK3β may be explored as a potential therapeutic target for AD through a mechanism that improves dopamine-dependent memory behaviors via modulating D2 receptor (D2R)-mediated signaling (Li et al., 2020), supporting the association to dopaminergic synapse pathway.